Group 1: Company Performance - In Q1 2025, the company achieved a revenue of 2.358 billion yuan, a year-on-year decline of 6.52% [5] - The net profit attributable to shareholders was 326 million yuan, an increase of 7.25% year-on-year [10] - The operating cash flow reached 340 million yuan, showing a significant increase of 190.67% [5] Group 2: R&D and Innovation - The company has maintained a continuous increase in R&D investment, having launched 5 innovative traditional Chinese medicines in the past four years [10] - Currently, there are 17 innovative patented traditional Chinese medicines covering seven major disease areas [3] - The company is focusing on enhancing its core technological innovation capabilities and optimizing its marketing system to maintain stable product gross margins [9] Group 3: Market Strategy - The company plans to expand the market for its core product, Lianhua Qingwen, by exploring new application scenarios and implementing a comprehensive brand marketing strategy [6] - Lianhua Qingwen has obtained approvals in over 30 countries and regions, with efforts to enhance its brand influence overseas [6] - Future product development will focus on respiratory, endocrine, digestive, gynecological, and pediatric diseases [6] Group 4: Policy and Industry Outlook - The Chinese government is promoting the development of traditional Chinese medicine (TCM) through various policies, including the "14th Five-Year Plan for TCM Development" [8] - The government has emphasized the importance of TCM in disease prevention, treatment, and health maintenance, which is expected to drive industry growth [7] - The overall policy environment is favorable for the high-quality development of the TCM industry, supporting innovation and structural optimization [8] Group 5: Investor Relations and Value Management - The company aims to align market value with intrinsic value through transparent information disclosure and effective investor relations management [9] - A stable and high-quality investor base is being established to maximize overall company benefits and shareholder wealth [9] - The company has a structured plan for sustainable and scientific returns to investors, considering multiple factors such as operational conditions and development goals [2]

Group 1 - The core initiative of Yiling Pharmaceutical is to promote the "Quality China" construction and high-quality development by enhancing brand recognition and storytelling for Chinese brands, particularly in the context of the upcoming "China Brand Day" in 2025 [3] - Yiling Pharmaceutical has launched the "5·10 Yiling Brand Month" series of activities in collaboration with nearly a hundred well-known chain pharmacies across the country, focusing on the theme "Technology Empowers Health, Brand Leads the Future" [3][4] - The activities will include public welfare science popularization, chronic disease management, and digital services to improve public health literacy and contribute positively to the construction of a healthy China [3][4] Group 2 - During the "5·10 Yiling Brand Month," Yiling Pharmaceutical will integrate quality medical resources through a multi-dimensional approach, including online science popularization and offline services, to provide comprehensive health service experiences for consumers [4] - The initiative will involve expert online live broadcasts and offline health screenings and consultations for chronic diseases, promoting the concept of "early screening, early diagnosis, early intervention" [4] - Yiling Pharmaceutical will collaborate with well-known chain pharmacies to conduct public health science roadshows across the country, aiming to enhance public access to health knowledge and services [4] Group 3 - Yiling Pharmaceutical has established a unique technological core competitiveness through the systematic construction of the theory of collateral diseases, which has led to significant technological innovations and the completion of multiple major projects [5][6] - The company has received six national science and technology awards and has developed patented new drugs for prevalent and major diseases, gaining recognition from clinical experts and patients [6] - Yiling's products, such as Lianhua Qingwen capsules and Tongxinluo capsules, have been approved for sale in over 50 countries and regions, showcasing the global reach of traditional Chinese medicine [6] Group 4 - As a national key high-tech enterprise, Yiling Pharmaceutical adheres to the principle of "inheritance and innovation for the benefit of humanity," actively engaging in social responsibility initiatives [7] - The company has achieved a water resource reuse rate of 97% through clean production and low-carbon energy practices, contributing to green development [7] - Yiling Pharmaceutical has created over 60 high-standard Chinese medicinal herb bases across more than 20 provinces, providing numerous job opportunities and revitalizing rural industries [7]

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].